Because lorlatinib has broader efficacy against common neuroblastoma ALK-mutated proteins and is now included in frontline neuroblastoma trials (20, 43), we next assessed the efficacy of combining TNO155 with lorlatinib. Here, ALK is linked to neuroblastoma.